Key statistics
As of last trade Beigene Ltd (49B:FRA) traded at 17.20, -14.85% below its 52-week high of 20.20, set on Feb 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.20 |
---|---|
High | 17.20 |
Low | 17.20 |
Bid | 17.60 |
Offer | 18.60 |
Previous close | 16.70 |
Average volume | 96.11 |
---|---|
Shares outstanding | 1.39bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 199.53bn HKD |
EPS (TTM) | -4.93 HKD |
Data delayed at least 15 minutes, as of Mar 13 2025 07:20 BST.
More ▼
Press releases
- TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
- BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
- BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
- TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
- BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
More ▼